Relief and resolve: Inside the Kiwis’ statement victory over Samoa - NZ Herald

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline – Novartis

October 26, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline NovartisNovartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports CNBCNovartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.comNovartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE) Seeking AlphaNovartis set to announce $10bn plus Avidity Biosciences purchase Financial Times